ClinicalTrials.gg
Status unknownNCT05645315Updated Dec 9, 2022

Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of TQB2618 injection and TQB2450 injection in Advanced Solid Tumor, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-09.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2022, registered Nov 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
127
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This project is a phase Ib clinical trial study evaluating the efficacy and safety of TQB2618 injection combined with TQB2450 injection in patients with advanced solid tumors, the trial plan to enroll 127 subjects, the trial design is a phase I.b dose exploration and cohort expansion clinical study, aiming to evaluate the safety and efficacy of TQB2618 injection combined with TQB2450 injection in patients with advanced malignant solid tumors, and to evaluate TQB2618 injection, Pharmacokinetic characteristics, receptor occupancy and immunogenicity characteristics of TQB2450 injection; Biomarker studies related to the mechanism of action, safety and/or pathological mechanism of efficacy have dose-limiting toxicity (DLT) in Phase I, recommended dose in Phase II (RP2D), and objective response rate (ORR) in Phase II as the primary endpoints.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily participated the study and signed the form;
  • Age: 18\~75 years old (when signing the informed consent form); PS score: 0\~1 points; Expected survival is more than 3 months;
  • The enrolled patients meet the following criteria:

    1. Satge I (dose exploration): patients with advanced malignant solid tumors confirmed by tissue and/or cytology, where standard therapy has failed or there is a lack of effective treatment;
    2. Stage 2 (cohort Expansion):

      1. Cohort 1: -positive patients with advanced NSCLC;
      2. Cohort 2: PD-L1 positive patients with advanced immunoresistant NSCLC;

        1. Patients with locally advanced (stage III.B/III.C), recurrent or (stage IV) NSCLC who are not or cytologically confirmed and are not suitable for radical concurrent chemoradiotherapy.
        2. For non-squamous non-small cell lung cancer, the test proves the absence of EGFR mutation, ALK fusion, ROS1 mutation (for squamous non-small cell lung cancer, patients with known mutations in the above genes are excluded, and testing is not mandatory for those whose status is unknown);
        3. Positive PD-L1 expression ratio≥1% [TC (tumor cells) or IC (immune cells) ≥1%];
        4. Cohort 1 advanced first-line patients: no systemic antitumor therapy for advanced disease.
        5. Patients with advanced immunoresistance in cohort 2: at least prior failure of platinum-containing chemotherapy and immune checkpoint inhibitor (PD-1 or PD-L1) therapy (combined or sequential therapy allowed)
  • at least one confirmed according to 1.1;
  • The main organs function normally
  • Female subjects of childbearing age should agree that must be used during the study and for 6 months after the end of the study

Exclusion criteria

Exclusion Criteria:

  • Comorbidities and medical history:

    1. Have received chemotherapy within 3 weeks before the first dose, radiotherapy (except palliative radiotherapy for non-target lesions) or other antineoplastic drugs within 2 weeks before the first dose (the is calculated from the end of the last treatment);
    2. Have developed or are currently suffering from other malignant tumors within 3 years before the first dose. The following two conditions can be enrolled: other treated with a single surgery, achieving 5 consecutive years of disease-free survival (DFS); cured carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor-invasive basement membrane)];
    3. unresolved toxicities above CTC AE grade 1 due to any prior treatment, excluding hair loss;
    4. Major surgical treatment and obvious traumatic injury within 28 days before the first dose;
    5. Wounds or fractures that have not healed for a long time;
    6. Arterioven/venous thrombotic events within 6 months prior to the first dose;
    7. Those with a history of psychotropic substance abuse and cannot quit or have mental disorders;
    8. Subjects with any severe and/or uncontrolled disease.
  • Tumor-related symptoms and treatment:

    1. Received proprietary Chinese medicine treatment with anti-tumor indications specified in the NMPA-approved drug instructions within 2 weeks before the first dose;
    2. Have received previous anti-TIM-3 antibody treatment;
    3. Have received previous immunotherapy drugs such as /PD-L1 antibody and anti-CTLA-4 antibody (only applicable to cohort 1 of the Stage II cohort expansion study: advanced NSCLC patients with positive PD-L1 expression);
    4. uncontrolled pleural effusion, pericardial effusion, or ascites that still requires repeated drainage (judged by the investigator);
    5. Known spinal cord compression, cancerous meningitis, with symptoms of or symptom control for less than 2 weeks;
  • Study treatment-related:

    1. History of within 28 days before the first dose or planned live attenuated vaccination during the study period;
    2. Those who have severe reactions after using macromolecular drugs;
    3. Active disease requiring systemic therapy within 2 years before the first dose (e.g., use of disease-modifying drugs, , or ); asthma patients requiring bronchodilators for medical intervention.
  • Those who have participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first dose;
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
127 participants (estimated)

Study arms

  • Experimental
    TQB2618 injection+TQB2450 injection

    TQB2618 injection combined with TQB2450 injection, 21 days as a treatment cycle.

    Drug: TQB2618 injection and TQB2450 injection

Interventions

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity

    The occurrence of severe toxicities during the first cycle of anti-cancer therapy

    Time frame: within the first treatment cycle for 21 days

  2. Phase II recommended dose

    Dose selection in the expansion phase

    Time frame: Through phase 1 completion, an average of half a year

  3. Objective response rate

    ORR is defined as the percentage of participants with progressive disease (PD) from first dose to first recorded or death from any cause of complete remission (CR) and partial remission (PR) based on investigator records

    Time frame: Up to 12 months

Secondary outcomes

  1. Progression-free survival

    PFS is defined as the time from randomization to the first recorded progressive disease (PD) or death from any cause.

    Time frame: Up to 12 months

  2. Disease control rate

    The time when participants first achieved full or partial remission of disease progression.

    Time frame: Up to 12 months

  3. Duration of remission

    The time from the start of the first evaluation of the tumor as Complete Response or Partial Response to the first assessment as Progressive Disease or death from any cause.

    Time frame: Up to 12 months

  4. Overall survival

    OS is defined as the time from randomization to death from any cause. Participants who did not die at the end of the extended follow-up period, or who lost follow-up during the study, were reviewed on the last date known to be alive.

    Time frame: Up to 18 months

  5. Maximum plasma drug concentration

    Maximum plasma drug concentration ia a pharmacokinetic parameter

    Time frame: 1 hour before and 30 minutes after TQB2450 injection administration; 30 minutes, 4, 8, 24, 48, 144, 312 hours after TQB2618 injection administration of cycle 1; 30 minutes after TQB2618 injection administration of cycle 2-8. Each cycle is 21 days.

  6. Immunogenicity

    Immunogenicity is evaluated by the detection of anti-drug antibodies (ADA) after administration

    Time frame: Each cycle is 21 days. 1 hour before administration of cycles 1, 2, 4, and 8, 1 hour before administration at the start of every 6 cycles thereafter; 30 and 90 days after the last dose.

  7. Free Tim3 receptors on the surface of CD3+ T cells

    TIM-3 receptor mass (RO) of TQB2618 on human immune cell membranes

    Time frame: before and 30 minutes after the end of administration of per cycle during cycles 1-8; when patients withdrawn from the group due to Progression Disease

  8. Adverse events (AEs)

    Occurrence rate of all adverse events

    Time frame: Up to 28 days after last dose or the initiation of a new antineoplastic therapy, whichever comes first

07

Study locations

2 of 5 sites recruiting
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Not yet recruiting
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450000, China
    Recruiting
  • Tongji Hospital,Tongji Medical College of HUST
    Wuhan, Hubei 430030, China
    Not yet recruiting
    • Qian Chu, Doctor · Contact13212760715
  • Hunan Cancer Hospital
    Changsha, Hunan 410005, China
    Recruiting
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2022 (actual). Primary completion is estimated for Dec 2023, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 9, 2022
StartActual
Apr 28, 2022
Primary completionEst.
Dec 2023
CompletionEst.
Jun 2024
Last update
Dec 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05645315
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Apr 28, 2022
Primary completion
Dec 2023 (estimated)
Completion
Jun 2024 (estimated)
Last update
Dec 9, 2022

Study contacts

Lin Wu, Doctor
Contact
wulin-calf@vip.163.com
+86 13170419973

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-TIM-3 Monoclonal Antibody TQB2618 · Benmelstobart

Start the discussion